Genmab, Incyte Partner On Trial Of Petosemtamab Combination In KRAS G12D-Mutated Colorectal Cancer
(RTTNews) - Genmab A/S (GMAB) and Incyte (INCY) have entered into a clinical trial collaboration to evaluate a novel combination therapy for patients with metastatic colorectal cancer (mCRC) harboring a KRAS G12D mutation, a population with significant unmet medical needs.
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.